Navigation Links
An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
Date:6/18/2013

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In patients with these mutations, PARP inhibitors, which are currently in clinical trials, have shown encouraging results that make them a new option for personalised cancer treatment, an alternative to standard chemotherapy. Nevertheless, the latest studies indicate that a fraction of these patients generate resistance to the drug and, therefore, stop responding to the new treatment.

The team led by Spanish National Cancer Research Centre researcher scar Fernndez-Capetillo, head of the Genomic Instability Group, together with researchers from the National Cancer Institute in the US, have participated in a study that describes the causes that explain why tumours with BRCA1 and BRCA2 mutations stop responding to PARP inhibitor drugs.

"PARP inhibitors are only toxic in tumours that have an impaired DNA repair mechanism, such as those that contain BRCA1/2 mutations" says Mara Nieto-Soler, a researcher from Fernndez-Capetillo's team.

According to the researchers, the problem arises when these tumours, in addition to having BRCA1 and/or BRCA2 mutations, also contain secondary mutations in other proteins such as 53BP1 or PTIP, whose function is to restrain DNA repair. In these cases, the mutations mutually compensate for each other, the tumour cells recover the ability to repair their DNA and the drug stops working.

Fernndez-Capetillo says: "This is one of the first studies to demonstrate that secondary mutations can make tumours resistant when faced with specific treatments like, in this case, PARP inhibitors".

NEW DIAGNOSTIC TESTS WITH SECONDARY MUTATIONS

When the researchers compared different treatments, they observed that for those tumours with BRCA1 and/or BRCA2 mutations that also presented mutations in 53BP1 or PTIP, standard treatment with cisplatin was more efficient than personalised therapy.

"These data indicate that only patients containing mutations in BRCA1 and/or BRCA2, but not in the secondary genes we have described, would be candidates for an effective personalised therapy with PARP inhibitors", explains Fernndez-Capetillo, concluding that: "Our results suggest that 53BP1 and PTIP genes would need to be evaluated in patients with familial breast and ovarian cancer when deficiencies in the BRCA genes were present before deciding on their treatment".

In this context, researchers intend to warn healthcare providers in personalised medicine that the challenge, in addition to the search for markers of drug sensitivity for new pharmacological compounds, also encompasses the search for secondary resistance markers. The aim would be to bring about significant improvements in treatment outcomes.


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related biology news :

1. 7 new GSA Bulletin articles posted online ahead of print
2. MU researchers develop radioactive nanoparticles that target cancer cells
3. GSAs top geoscience journal posts 9 new articles
4. Microscopic dust particles found in underground railways may pose health risk
5. Long-term exposure to fine particles of traffic pollution increases risk of heart disease
6. Ultrafine particles raise concerns about improved cookstoves
7. Transmission routes of spreading protein particles
8. Trackable drug-filled nanoparticles -- a potential weapon against cancer
9. Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online
10. PeerJ publishes its first articles
11. From grains of volcanic glass to continental rifting: New Geosphere articles now online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and ... ... to 16 March, Materna will present its complete end-to-end passenger ... is a real benefit for passengers. To accelerate the whole ... touch point solutions to take passengers through the complete integrated ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... tissue regeneration from small lab samples to full-size tissues, bones, even whole organs ... a vascular system that delivers blood deep into the developing tissue. , ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... March 22, 2017 /PRNewswire/ - FACIT announced a ... or "Propellon"), a start-up created by FACIT focused ... FACIT,s investment, combined with non-dilutive capital, achieves a ... seed funding enables Propellon to accelerate the nomination ... for financing and/or entering a strategic partnership for ...
Breaking Biology Technology: